In a significant development for oncology, researchers have identified specific blood-based biomarkers that distinguish inflammatory breast cancer (IBC) from other subtypes. This breakthrough, detailed in Science Advances, offers a new, less invasive method for early diagnosis, monitoring disease progression, and informing future treatment strategies for patients facing this particularly aggressive form of the disease.
Inflammatory breast cancer is widely recognized by clinicians as one of the most lethal and aggressive forms of breast cancer. Historically, it has been notoriously difficult to study because its genetic mutations often mirror those of non-inflammatory breast cancer, making it challenging to differentiate the two using standard genomic sequencing techniques. Conventional RNA-sequencing methods rely on enzymes that often struggle to process complex RNA, leading to significant data loss and fragmented results.
To overcome these obstacles, a research team led by scientists at The University of Texas at Austin utilized a specialized sequencing method known as Thermostable Group II Intron Reverse Transcriptase (TGIRT) sequencing. This approach employs a robust enzyme capable of operating in extreme environments, allowing for a more comprehensive overview of all RNA types and amounts present in a sample. The study was conducted in collaboration with experts at The University of Texas MD Anderson Cancer Center and the University of Hawai’i Cancer Center, with funding from organizations including the National Institutes of Health (NIH) and the Breast Cancer Research Foundation.
Advanced Sequencing and the Liquid Biopsy Potential
The application of TGIRT sequencing has provided researchers with a more reliable way to capture and analyze complex, fragmented RNAs that were previously missed by standard clinical methods. By analyzing protein-coding genes specific to IBC tumors, the team identified distinct signatures that set this cancer apart from other breast cancer subtypes.
According to Savitri Krishnamurthy, professor of anatomic pathology at The University of Texas MD Anderson Cancer Center, the findings offer a vital new path for patient care. “These findings provide new insights into inflammatory breast cancer that should enable clinicians to monitor disease progression simply through liquid biopsy,” Krishnamurthy stated. She added, “Because This proves so difficult to obtain tumor samples, these blood-based biomarkers could be truly transformative in developing treatments for this patient population.”
Key Biological Distinctions
The research revealed that blood samples from patients with IBC displayed high levels of noncoding RNAs and an increased presence of white blood cells compared to healthy individuals or those with non-inflammatory breast cancer. These patterns suggest that the immune system is actively responding to the disease and that We find significant imbalances in RNA splicing—a process that normally helps regulate gene activity.
Specifically, the researchers observed that plasma samples from IBC patients contained an overrepresentation of intron RNA fragments—the noncoding segments of genes that are typically spliced out. In contrast, blood samples from healthy donors primarily contained mRNA fragments, which are the products of messenger RNA degradation. These distinct RNA profiles provide a potential “fingerprint” for identifying the presence and progression of inflammatory breast cancer through a simple blood draw rather than more invasive tissue biopsies.
Looking Ahead: Implications for Therapeutic Development
The ability to identify these biomarkers in peripheral blood cells and plasma represents a meaningful step toward personalized medicine for IBC patients. By better understanding the unique features of this aggressive subtype, researchers hope to develop more effective therapeutic strategies that target the specific biological mechanisms driving the disease.
This study represents a collaborative effort involving the Morgan Welch Inflammatory Breast Cancer Research Program and Clinic at MD Anderson, as well as support from The Welch Foundation and the State of Texas Rare and Aggressive Breast Cancer Research Program. As the medical community continues to refine these diagnostic tools, the focus remains on translating these laboratory findings into clinical applications that can improve outcomes for those diagnosed with inflammatory breast cancer.
The research team has made the full list of collaborating authors and their disclosures available alongside the publication in Science Advances. Further updates regarding the clinical validation of these biomarkers are expected as the research progresses through subsequent phases of study. We invite our readers to share their thoughts on these developments in the comments section below.